Intas & Accord Expand Global Pegfilgrastim Reach with UDENYCA Acquisition

Intas Pharmaceuticals and its U.S. specialty arm, Accord BioPharma, have announced the successful acquisition of UDENYCA® (pegfilgrastim-cbqv) from Coherus BioSciences. This move strengthens their position as one of the world’s leading suppliers of pegfilgrastim biosimilars.

Key Highlights:

• Biosimilar Expansion: UDENYCA, a pegfilgrastim biosimilar, helps reduce infection risk in cancer patients undergoing chemotherapy and improves survival after radiation exposure.

• Multiple Formulations: Now available in three formats—autoinjector, on-body injector, and prefilled syringe—enhancing treatment convenience for patients. More than 1.4 million units have already been distributed, benefitting over 300,000 patients.

• Smooth Transition: Employees from Coherus across sales, marketing, supply chain, and manufacturing have joined Accord, ensuring continuity and growth.

• Global Leadership: Accord is already a leader in pegfilgrastim biosimilars in Europe and was the first to launch the autoinjector. The acquisition significantly boosts its U.S. and worldwide presence.

Management Commentary:

• Binish Chudgar, Chairman & MD of Intas, said the deal cements the company’s global leadership in pegfilgrastim.

• Chrys Kokino, U.S. President of Accord, called it a pivotal moment that strengthens their presence in the U.S. market.

• Paul Tredwell, EVP of Accord EMENA, highlighted that offering UDENYCA in three formulations brings them closer to becoming the world’s leading pegfilgrastim supplier.